XPH(SZ:300147)2023-04-21 16:00Financial Performance - The company achieved operating revenue of CNY 2,187,069,901.40, a decrease of 26.38% year-on-year[23]. - The net profit attributable to shareholders was CNY -533,158,456.93, an increase of 22.56% compared to the previous year[23]. - The cash flow from operating activities was CNY 227,377,262.86, down 11.72% from the previous year[23]. - The total assets at the end of 2022 were CNY 9,353,000,538.98, a decrease of 17.82% from the end of 2021[23]. - The net assets attributable to shareholders decreased by 18.35% to CNY 2,405,133,051.46 compared to the end of 2021[23]. - The basic earnings per share were CNY -0.81, an improvement of 22.12% from CNY -1.04 in the previous year[23]. - The total amount of non-recurring gains and losses for 2022 was approximately $19.95 million, a decrease from $42.11 million in 2021[29]. - The company reported a significant reduction in soft drink sales, with a 93.7% decrease in sales volume and a 100% drop in production volume[65]. - The company reported a total revenue of 3.689 billion CNY for the year 2022, reflecting a significant performance in the pharmaceutical sector[132]. - The company reported a total of 16,520,000 CNY for expected daily related transactions in 2022, with actual transactions amounting to 5,793,240 CNY for goods sold and 1,029,870 CNY for leasing[194]. Business Strategy and Operations - The company continues to focus on its core business despite challenges from the macro environment and rising raw material prices[3]. - The company emphasizes that its core competitiveness and main business have not undergone significant adverse changes[3]. - The company is focused on the modernization and industrialization of traditional Chinese medicine, supported by government policies aimed at enhancing the sector's development[32]. - The company is engaged in the research and development of T-cell immunotherapy drugs, with ongoing projects targeting soft tissue sarcoma and primary liver cancer[35]. - The company has established a comprehensive supply chain management system for the procurement of traditional Chinese medicine materials, ensuring quality and stability in supply[36]. - The company has maintained a stable product line, including antiviral oral liquids and various traditional Chinese medicine products, with no significant changes reported during the period[35]. - The company aims to modernize traditional Chinese medicine and expand its industry chain, including establishing standardized processing bases and logistics[96]. - The company is focusing on precision medicine, collaborating with medical institutions to develop clinical research projects and treatment centers[96]. - The company plans to explore new medical service models, including telemedicine and smart healthcare, to integrate resources from traditional and Western medicine[96]. - The company will focus on its core business, optimizing resource allocation to enhance scale efficiency and improve market share in the cold and cough product segments[98]. Research and Development - Ongoing clinical trials include KX02 for malignant glioma and a high-affinity TCR cell therapy for soft tissue sarcoma, indicating active R&D efforts[43][44]. - The company has established a complete TCR-T technology platform, achieving international advanced levels in tumor immunotherapy[45]. - The company’s subsidiary, Xiangxue Life Sciences, has a TCR-T cell immunotherapy product, TAEST16001, which is currently in Phase II clinical trials[57]. - The total R&D investment as a percentage of operating income increased to 6.12% from 4.60% in 2021[76]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical industry[135]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[113]. - The company emphasizes the importance of information disclosure, adhering to regulations to provide accurate and timely information to investors[119]. - The company maintains good communication with investors through various channels, including performance briefings and investor visits, to keep them informed about its strategic direction and business developments[120]. - The company has received a warning from the China Securities Regulatory Commission regarding non-compliance with disclosure obligations, which highlights the need for improved governance[135]. - The company has established a compensation committee to determine the remuneration of directors and senior management based on performance and responsibilities[139]. Legal and Regulatory Issues - The company faces multiple legal disputes, including a significant lawsuit involving 300 million yuan related to investment rights and another arbitration case involving approximately 280 million yuan, which could affect its financial standing[108][109]. - The company has pledged assets such as the Yunpu plant and the Biological Island No. 1 plot to cover the amounts involved in the lawsuits, indicating a proactive approach to managing legal risks[109]. - The company has been fined 250,000 yuan for violating advertising laws, but this is not expected to have a major impact on operations[190]. - The company is actively seeking reasonable solutions for ongoing litigation and has engaged a professional legal team to protect its rights[191]. Employee and Management - The total number of employees at the end of the reporting period was 2,417[150]. - The company has a comprehensive annual training plan focusing on employee development, covering various skills and management capabilities[152]. - The company has optimized its training system to enhance employee learning efficiency and engagement through internal resources and new technologies[152]. - The company has established a performance evaluation system for senior management, with the compensation committee responsible for determining annual remuneration based on operational performance and management indicators[161]. Environmental Responsibility - The company invested approximately 1.35 million yuan in wastewater treatment, environmental testing, and solid/hazardous waste management in 2022[174]. - The company has implemented a wastewater treatment facility with a design capacity of 360 m³/d, ensuring compliance with national standards[172]. - The company reported no major environmental penalties during the reporting period[174]. - The company actively promotes green practices and resource efficiency, reflecting its commitment to environmental responsibility[175].